In addition to diabetes, increased O-GlcNAc levels have been reported in different experimental models of hypertension (6, 20, 21), cardiac hypertrophy (22, 23), cardiac dysfunction (22, 24, 25), as well as in response to agonists such as angiotensin II (Ang II) (6) and endothelin-1 (ET-1) (9, 10). This evidence concerns the gene EDN1 and Hypertension.